Keros Therapeutics and Takeda signed a license agreement for elritercept, excluding Macau and mainland China from commercialization.
3 reports, 2 independent
Updated Aug 14
Gone quiet
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Keros Therapeutics and Takeda signed a license agreement for elritercept, excluding Macau and mainland China from commercialization.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
KROS
Slovak company
Nothing else this week.
-
Takeda Pharmaceutical Company
Japanese pharmaceutical company
Nothing else this week.
Coverage
Newest first; wire copies grouped- yahoo.com
- GlobeNewswireKeros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept Milestone payment of $10 million triggered under the global license agreement with Takeda LEXI